Toronto Stock Exchange Symbol: AKL
MONTREAL, Nov. 9 /CNW Telbec/ - Akela Pharma Inc. (TSX: AKL), a drug
development company focused on developing therapies for the inhalation and
pain markets, today announced its financial results under Canadian generally
accepted accounting principles for the three and six month period ended
September 30, 2007 and 2006.
Akela's consolidated net loss for the third quarter of 2007 was
$8.6 million compared to net income of $12.0 million for the segmented Pharma
results for the same 2006 period. The results of operations for the three and
nine months ended September 30, 2006 include a gain on disposal of our
interest in LAB Research totaling $18.6 million.
"The Third quarter fiscal 2007 was marked by important clinical
achievements. We first announced positive results from our GHRH Phase II trial
demonstrating a marked stimulation of growth hormone and IGF-1 production
followed by positive results for our lead product Fentanyl TAIFUN(R) for the
Phase IIb extension arm trial demonstrating efficacy resulting in faster and
superior pain relief. Having once again delivered significantly positive
clinical milestones we now continue to confidently advance our product
development programs." said Dr Halvor Jaeger, Chief Executive Officer of Akela
Other Third Quarter Financial Highlights
- Total consolidated revenues for the third quarter of 2007 were
$3.1 million, including $1.1 million in co-development fees and
$1.9 million of contract services. Total consolidated revenues for the
first 9 months of 2007 were $7.9 million, including $1.6 million in
co-development fees and $5.7 million of contract services.
- Consolidated net loss for the third quarter of 2007 was $8.6 million or
($0.73) per share. Consolidated net loss year-to-date is $23.8 million
or ($2.03) per share.
2007 Third Quarter Operational Highlights
- Akela announced the signing of a licensing agreement with Janssen
Pharmaceutica NV for its lead product, Fentanyl TAIFUN(R) for the
European Union, Eastern Europe, Russia, the Middle East and Africa. A
signing fee of $10.8 million was received.
- Akela announced the change of its corporate name from LAB International
Inc. following the approval of a special resolution at its Annual and
Special Shareholders meeting.
- Akela announced positive interim results from its pilot GHRH Phase II
study producing within 4 weeks of treatment a highly significant
stimulation of endogenous growth hormone (GH) secretion and a marked
increase of circulating insulin-like growth factor (IGF-1) as compared
- Akela announced positive results from its Fentanyl TAIFUN(R) Phase IIb
extension arm demonstrating statistically significant differences
compared to placebo in the measured primary and secondary efficacy
variables resulting in faster and superior pain relief.
The year-over-year increase in the net loss was due to a higher rate of
spending on research and development activities and selling, general and
Consolidated SG&A expenses totaled $4.0 million for the third quarter of
2007 and $10.5 million year-to-date compared to $2.9 million and $11.0 million
for the same respective 2006 periods.
R&D costs for the third quarter of 2007 were $5.7 million and
$15.4 million year-to-date compared to $2.8 million and $7.6 million for the
same respective 2006 periods. The year-to-date amount includes $1.6 million of
severance expense and early termination charges relating to the exit of leased
premises in Finland. The increase in spending is primarily attributable to the
costs associated with the advancement and finalization of the Fentanyl
TAIFUN(R) Phase II trial program and the development of our product
The consolidated net loss for the third quarter of 2007 was $8.6 million,
or ($0.73) per share and $23.8 million or ($2.03) per share year-to-date,
compared with a consolidated net income for the former Pharma segment of
$12.0 million and $0.8 million, respectively.
The Company had cash and cash equivalents as of September 30, 2007 of
$15.1 million. compared with $35.3 million as of December 31, 2006.
THE ISSUER HAS FILED A REGISTRATION STATEMENT (INCLUDING A PROSPECTUS)
WITH THE SEC (FILE NO. 333-146684) FOR AN OFFERING OF ITS SECURITIES. BEFORE
YOU INVEST, YOU SHOULD READ THE PROSPECTUS IN THAT REGISTRATION STATEMENT AND
OTHER DOCUMENTS THE ISSUER HAS FILED WITH THE SEC FOR MORE COMPLETE
INFORMATION ABOUT THE ISSUER AND THIS OFFERING. YOU MAY GET THESE DOCUMENTS
FOR FREE BY VISITING EDGAR ON THE SEC WEB SITE AT WWW.SEC.GOV. ALTERNATIVELY,
THE ISSUER, ANY UNDERWRITER OR ANY DEALER PARTICIPATING IN THE OFFERING WILL
ARRANGE TO SEND YOU THE PROSPECTUS IF YOU REQUEST IT BY CONTACTING OPPENHEIMER
AND CO. INC. AT 125 BROAD STREET, 16TH FLOOR, NEW YORK, NEW YORK 10004,
ATTENTION: SYNDICATE DEPARTMENT, OR BY PHONE AT (212) 825 4341
About Akela Pharma Inc.
Akela Pharma is an integrated drug development company focused on
developing therapies for the growing multi-billion dollar inhalation and pain
markets. Its lead product, for the treatment of breakthrough cancer pain, is a
fast-acting Fentanyl formulation delivered using the Company's TAIFUN(R) dry
powder inhaler platform. Its pipeline also includes therapeutics for asthma,
COPD, growth hormone deficiencies and controlled substance abuse deterrent
Akela's common shares trade on The Toronto Stock Exchange ("TSX") under
the symbol "AKL" with 11.7 million shares outstanding.
This news release contains certain forward-looking statements that
reflect the current views and/or expectations of Akela Pharma Inc. with
respect to its performance, business and future events. Such statements are
subject to a number of risks, uncertainties and assumptions. Actual results
and events may vary significantly.
For further information:
For further information: Frédéric Dumais, Vice-President, Investor
Relations, (514) 315-3330 ext. 106, Fax: (514) 315-3325, www.akelapharma.com